Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual latanoprost for reduction of intraocular pressure in glaucoma
IRCT20241015063374N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of latanoprost in Glaucoma, sponsored by Shahid Beheshti University of Medical Sciences. Started Nov 2024; status: completed.
02
Drugs
latanoprost
03
Conditions
Glaucoma
Beyond the preview
Go deeper on IRCT20241015063374N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241015063374N1.